Patents by Inventor Susan B. Sobolov-Jaynes

Susan B. Sobolov-Jaynes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING AMYLOIDOSIS
    Publication number: 20230364228
    Abstract: Provided herein are methods of treating amyloidosis disease and disorder in a subject, and methods of decreasing the amount of amyloid deposits in an organ. The methods provided herein include the administration of an antibody, alone or in combination with another therapy. In one aspect, the disclosure provides a method of treating an amyloidosis disease or disorder in a subject including administering to the subject the pharmaceutical composition of the invention and an additional therapy, thereby treating the amyloidosis disease or disorder in the subject.
    Type: Application
    Filed: September 14, 2021
    Publication date: November 16, 2023
    Inventors: Michael Spector, Susan B. Sobolov-Jaynes, Michael Kahsai, Anthony S. Lubiniecki, Jessica G. Raviwong
  • Combination treatment for depression and anxiety
    Publication number: 20040220274
    Abstract: The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and an anxiolytic agent or antidepressant.
    Type: Application
    Filed: May 28, 2004
    Publication date: November 4, 2004
    Applicant: Pfizer Inc.
    Inventor: Susan B. Sobolov-Jaynes
  • Combination treatment for depression and anxiety
    Publication number: 20040006135
    Abstract: The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with an NK-3 antagonist agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and an NK-3 antagonist.
    Type: Application
    Filed: March 12, 2003
    Publication date: January 8, 2004
    Applicant: Pfizer Inc.
    Inventors: Susan B. Sobolov-Jaynes, John A. Lowe, Stafford McLean
  • Combination treatment for depression and anxiety
    Publication number: 20040001895
    Abstract: The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with a PDE IV inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and a PDE IV inhibitor.
    Type: Application
    Filed: March 13, 2003
    Publication date: January 1, 2004
    Applicant: Pfizer Inc.
    Inventors: Susan B. Sobolov-Jaynes, Christopher J. Schmidt, Lorraine A. Lebel
  • Combination treatment for depression and anxiety
    Publication number: 20030235631
    Abstract: The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a PDE IV inhibitor in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a PDE IV inhibitor and an anxiolytic agent or antidepressant.
    Type: Application
    Filed: March 12, 2003
    Publication date: December 25, 2003
    Applicant: Pfizer Inc.
    Inventors: Susan B. Sobolov-Jaynes, Christopher J. Schmidt
  • Heterocyclic ring-fused pyrimidine derivatives
    Patent number: 6395733
    Abstract: The present invention relates to heterocyclic ring-fused pyrimidine derivatives of formula (I) or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof, wherein Z and Y are as defined in the specification.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: May 28, 2002
    Assignee: Pfizer Inc
    Inventors: Lee Daniel Arnold, Mikel P. Moyer, Susan B. Sobolov-Jaynes
  • 4-aminoquinazolone derivatives
    Patent number: 6225318
    Abstract: This invention relates to certain 4-aminoquinazoline derivatives of the formula and their pharmaceutically acceptable salts wherein R1, Q1, m, n, and Z are defined as in the specification. The compounds of formula I and pharmaceutically acceptable salts are useful for the treatment of hyperproliferative disorders and conditions in mammals.
    Type: Grant
    Filed: November 26, 1999
    Date of Patent: May 1, 2001
    Assignee: Pfizer Inc
    Inventors: Susan B. Sobolov-Jaynes, Lee D. Arnold